EN 122002

Drug Profile

EN 122002

Latest Information Update: 27 Jun 2013

Price : $50

At a glance

  • Originator Protemix Corporation
  • Class Hormones
  • Mechanism of Action Insulin growth factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Jun 2010 Discontinued - Preclinical for Type-2 diabetes mellitus in New Zealand (unspecified route)
  • 25 Aug 2003 This compound is still in active development
  • 14 Nov 2001 Preclinical development for Type-2 diabetes mellitus in New Zealand (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top